Ecopro BM Conducts 1.2 Trillion Won Paid-In Capital Increase... 915 Billion Won Allocated for 'Acquisition of Other Entities' Shares'
Ecopro BM will carry out a paid-in capital increase of approximately 1.2 trillion won to secure funds for facility investment, operating capital, and the acquis

Ecopro BM will carry out a paid-in capital increase of approximately 1.2 trillion won to secure funds for facility investment, operating capital, and the acquisition of shares in other entities.
■ 0.091 Shares Allocated Per Share... Final Price to Be Determined on October 12 This paid-in capital increase will be conducted through a method of allocating shares to existing shareholders first, followed by a public offering of unsubscribed shares. The total number of issued shares prior to the capital increase is 97,830,434, and the number of newly issued common shares is 9,909,990.
Existing shareholders will be allocated 0.0910905009 new shares per share, while the employee stock ownership association will receive a priority allocation of 10% of the total shares offered. The scheduled issue price is 121,200 won per share, and the final issue price will be determined on October 12.
- *■ Detailed Breakdown by Use of Funds**
- The total 1.2 trillion won to be raised will be allocated as follows.
- Acquisition of securities in other entities: 915 billion won
- Facility investment funds: 150 billion won
- Operating funds: Approximately 135 billion won
- *■ Key Subscription and Listing Schedule**
- New share allocation record date: September 4, 2026
- Subscription period: October 15 – 16 (for employee stock ownership association and existing shareholders)
- Public offering of unsubscribed shares: October 20 – 21 (if unsubscribed shares occur)
- Payment date: October 23
- Scheduled new share listing date: November 5
■ Lead Managers and Other Notes Korea Investment & Securities, NH Investment & Securities, Mirae Asset Securities, and Daishin Securities are serving as lead managers, while Meritz Securities and Hana Securities are participating as co-managers. Additionally, the subscription warrants are transferable and are slated to be listed on the Korea Exchange.
Meanwhile, according to the disclosure, some schedules or details may be subject to change depending on consultations with relevant authorities and the review process for the securities registration statement.
CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.
![[Breaking] Samsung Pharmaceutical Submits Domestic Phase 3 Clinical Trial Plan for Progressive Supranuclear Palsy Treatment 'GV1001'... Targeting 204 Patients](https://media.cbcglobe.com/tenants/cbc00000-0000-4000-8000-000000000001/media/cbc/2026/06/579545/36de0fb87055dd02/variants/hero.webp)
![[Breaking] LG Chem Submits Regulatory Approval Application for Type 2 Diabetes Triple-Combination Drug 'Zemidapaem ER Tablet'](https://media.cbcglobe.com/tenants/cbc00000-0000-4000-8000-000000000001/media/cbc/2026/06/581031/0c2a8f5a6d5bef88/variants/hero.webp)

